Terazosin Analogs Targeting Pgk1 as Neuroprotective Agents: Design, Synthesis, and Evaluation.
PGK1
agonist
drug design
neuroprotection
nitrogen-containing heterocyclic compounds
Journal
Frontiers in chemistry
ISSN: 2296-2646
Titre abrégé: Front Chem
Pays: Switzerland
ID NLM: 101627988
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
03
2022
accepted:
13
06
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
epublish
Résumé
Nitrogen-containing heterocyclic compounds have shown promising therapeutic effects in a variety of inflammatory and neurodegenerative diseases. Recently, terazosin (TZ), a heterocyclic compound with a quinazoline core, was found to combine with phosphoglycerol kinase 1 (Pgk1) and protect neurons by enhancing Pgk1 activity and promoting glycolysis, thereby slowing, or preventing the neurodegeneration of PD. These findings indicated that terazosin analogs have bright prospects for the development of PD therapeutics. In this study, a series of terazosin analogs were designed and synthesized for neuroprotective effects by targeting Pgk1. Among them, compound
Identifiants
pubmed: 35958233
doi: 10.3389/fchem.2022.906974
pii: 906974
pmc: PMC9360532
doi:
Types de publication
Journal Article
Langues
eng
Pagination
906974Informations de copyright
Copyright © 2022 Wang, Qian, Zhao, Wang and Li.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
CNS Drugs. 2016 Dec;30(12):1127-1135
pubmed: 27826740
Molecules. 2017 Jun 21;22(6):
pubmed: 28635653
Redox Biol. 2018 Jun;16:47-58
pubmed: 29475134
Neurobiol Dis. 2009 May;34(2):230-44
pubmed: 19385055
Bioorg Chem. 2021 Mar;108:104614
pubmed: 33508678
Nat Chem Biol. 2015 Jan;11(1):19-25
pubmed: 25383758
Eur J Med Chem. 2022 Jan 5;227:113949
pubmed: 34742016
J Clin Neurosci. 2020 May;75:1-4
pubmed: 32247740
Lancet. 2015 Aug 29;386(9996):896-912
pubmed: 25904081
Acta Med Port. 2019 Oct 1;32(10):661-670
pubmed: 31625879
Nat Commun. 2014 Oct 21;5:5181
pubmed: 25333748
Int J Neuropsychopharmacol. 2006 Feb;9(1):51-61
pubmed: 15927086
Brain Res Bull. 2019 Oct;152:11-18
pubmed: 31136787
Life Sci. 2019 Jun 1;226:77-90
pubmed: 30980848
Curr Neuropharmacol. 2019;17(3):295-306
pubmed: 30479218
J Clin Invest. 2019 Oct 1;129(10):4539-4549
pubmed: 31524631
Clin Neuropharmacol. 2020 Jul/Aug;43(4):100-106
pubmed: 32658035
Cells. 2020 Jan 17;9(1):
pubmed: 31963435
Biochim Biophys Acta. 2014 Aug;1842(8):1282-94
pubmed: 24060637
Expert Opin Ther Targets. 2011 Dec;15(12):1405-18
pubmed: 22148952